

PROGRAM MATERIALS REQUIREMENTS

Retina World Congress Webinar Series - "Cell+Gene Therapy: Changing Your World"

Sunday, August 28, 2022



This activity is jointly provided by Clinical and Patient Educators Association and iVista.

This activity is supported by an educational grant from Alcon, Apellis, Regeneron, and REGENXBIO.

Target Audience

Retina specialists, comprehensive ophthalmologists, retina fellows and residents, and healthcare providers who are interested in applying the most recent advancements in the retinal medicine field, including emerging techniques for imaging and treatments for retinal and vitreoretinal diseases.

Statement of Need/Program Overview

The CME webinar series creates an educational environment with the cutting-edge clinical data, translational research, and practical information for retina specialists to optimize patient care around the world. New discoveries on molecular pathways and therapies have revolutionized retina care by optimizing visual gain and reducing treatment burden. Moreover, advances in imaging have led to a better understanding of retina disease pathogenesis, diagnosis, and treatment. Each webinar will be based on recent clinical trial data and best clinical practice to prevent, treat, and cure blindness caused by retina disease.

Educational Objectives

After completing this activity, the participant should be better able to:

- Evaluate innovative gene and cell therapies to prepare for their entry to treat retinal diseases
- Evaluate innovative therapies and delivery systems based on their ability to improve durability and maintain visual outcomes.

Faculty

Jeffrey Heier, MD
Ophthalmic Consultants of Boston

Christine Kay, MD
Vitreoretinal Associates

Peter Kaiser, MD
Cole Eye Institute, Cleveland Clinic

Arshad M. Khanani, MD, MA
Sierra Eye Associates

Jorge Rocha, MD, PhD
iRetina Eye Institute, President

Program Agenda

8:00 PM Welcome
8:01 PM Introduction to Webinar and Panelists Peter Kaiser, MD
8:03 PM Speaker 1: Christina Kay, MD
8:23 PM Discussion
8:30 PM Speaker 2: Jeffrey Heier, MD
8:50 PM Discussion
9:00 PM Speaker 3: Arshad M. Khanani, MD, MA
9:20 PM Discussion
9:28 PM Closing Remarks Peter Kaiser, MD and Jorge Rocha, MD, PhD

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Clinical and Patient Educators Association (CPEA) and iVista. CPEA is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Clinical and Patient Educators Association designates this live activity for a maximum of 1.5 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CPEA Contact Information

For information about the accreditation of this program, please contact CPEA at 303-953-4580 or inquire@cpea-assn.org

Instructions for Obtaining Credit

In order to receive credit, participants complete the post test and evaluation: <https://ivista.digitellinc.com/ivista/live/160/page/1038>.

System Requirement

PC

1.4 GHz Intel Pentium 4 or faster processor (or equivalent)
Windows 10, 8.1 (32-bit/64-bit), Windows 7 (32-bit/64-bit)
512 MB of RAM (1 GB recommended)
Microsoft Internet Explorer 11 or later, Windows Edge browser, Mozilla Firefox, and Google Chrome
For HTML Client – Google Chrome (v70.0 & above), Mozilla Firefox (v65.0 & above), and Edge (v42.0 & above)

MAC

1.83 GHz Intel Core Duo or faster processor
512 MB of RAM (1 GB recommended)
MAC OS X 10.12, 10.13 and 10.14
Mozilla Firefox, Apple Safari, Google Chrome
For HTML Client – Google Chrome (v70.0 & above), Apple Safari (v12.0 & above), and Mozilla Firefox (v65.0 & above)

Fee Information& Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Conflicts of Interest

Clinical and Patient Educators Association (CPEA) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by CPEA are required to disclose all financial relationships with any ineligible company within the past 24 months to CPEA. All financial relationships reported are identified as relevant and mitigated by CPEA in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by CPEA to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The **faculty** have the following relevant financial relationships with ineligible companies:

Name of Faculty or Presenter	Reported Financial Relationship
Jeffery Heir	Consulting Fee (e.g., Advisory Board): 2020 Onsite, 4DMT, Abpro, Adverum, Affamed, AGTC, Akuous, Allegro, Allergan, Annexon, Apellis, Asclepix, Bionic Vision Technologies, Biovisics, Ciana, Curacle, DTx, Gemini, Genentech, Graybug, Gyroscope, Iveric, Janssen R&D, Kriya, Nanoscope, NGM, Notal Vision, Novartis, OcuTerra, OliX, Palatin, Perceive Therapeutics, Regenxbio, Regeneron, RetinAI, RevOpsis, Stealth Biotherapeutics, Thea, Unity Bio, Vanotech Contracted Research (Principal Investigators must provide information, even if received by the institution): Annexon, Apellis, AsclepiX, Bayer, Genentech/Roche, Gyroscope, Iveric, jCyte, Kodiak, NGM, Notal Vision, Regeneron, Regenxbio Stock Shareholder (Individual stocks/Stock options; diversified mutual funds do not need to be disclosed): Adverum, DTx Pharma, Ocular Therapeutix Stock Option Holder (Individual stocks/Stock options; diversified mutual funds do not need to be disclosed): Aldeyra, Allegro, Aviceda, jCyte, RevOpsis, Vinci, Vitranu
Peter Kaiser	Consulting Fee (e.g., Advisory Board): Aerie, AffaMed Therapeutics, Applied Genetic Technologies Corporation (AGTC), Allegro, Allergan, Allgenesis, Alnylam Pharmaceuticals, Alzheon, Annexon Biosciences, AsclepiX, Aviceda, Bayer, Bausch and Lomb, Biogen Idec, Bionic Vision Technologies, Boerenger Ingelheim, Carl Zeiss Meditec, Clearside Biomedical, Coherus, DelSiTech, Dompe, DTx Pharma, Duet Therapeutics, Eyevensys, Galecto Biotech, Galimedix, Glaukos, Innovent, iRenix, IvericBio, jCyte, Kanaph Therapeutics, Kanghong, Kera Therapeutics, Kodiak, Kriya Therapeutics, LensGen, Nanoscope Therapeutics, Novartis, Ocugenix, Ocular Therapeutics, Oculis, Ocuphire, OcuTerra Therapeutics, Omeros, Oxurion, Palatin, Regeneron, RegenxBio,

	Resonance Medicine Inc., Retinal Sciences, Retrope, Roivant, Samsung Bioepis, SGN Nanopharma Inc., Stealth Biotherapeutics, Stuart, Sustained Nano Systems, Takeda, Théa, Unity Biotechnology, 2020 Onsit
Christine Kay	<p>Consulting Fee (e.g., Advisory Board): Atsena Therapeutics, Kiora Pharmaceuticals, 4D Therapeutics, AGTC</p> <p>Contracted Research (Principal Investigators must provide information, even if received by the institution): 4D Therapeutics, RegenxBio, Gyroscope, AGTC, Alkeus, ProQR Therapeutics, Iveric Bio, Kodiak, MeiraGTX, Janssen, Biogen, Novartis, Stargazer</p> <p>Speakers' Bureau: Spark Therapeutics</p> <p>Stock Option Holder (Individual stocks/Stock options; diversified mutual funds do not need to be disclosed): Atsena Therapeutics, Kiora Pharmaceuticals</p>
Arshad Khanani	<p>Consulting Fee (e.g., Advisory Board): Adverum, Aerpio, Alimera, Allergan, Apellis, Asclepix, Aviceda, Bausch and Lomb, Broadwing Bio, Chengdu Kanghong, Cholgene, 4DMT, Dutch Ophthalmic Research Center, Gemini, Genentech, Glaukos, Graybug, Gyroscope, Iveric Bio, Janssen, Kato Pharma, Kodiak, Oculis, Opthea, Oxurion, Novartis, Polyphotonix, Recens Medical, Regeneron, Retrotope, Regenxbio, Roche, Surrozen, Thea, Unity Bio</p> <p>Contracted Research (Principal Investigators must provide information, even if received by the institution): Adverum, Apellis, Asclepix, Chengdu Kanghong, 4DMT, Gemini, Genentech, Graybug Vision, Gyroscope, Iveric Bio, Kodiak, Neurotech, NGM Bio, Ocular Therapeutix, Oculis, Opthea, Oxurion, Novartis, Recens Medical, Regenxbio, Roche, Unity Bio</p> <p>Speakers' Bureau: Allergan, Genentech, Novartis</p> <p>Stock Option Holder (Individual stocks/Stock options; diversified mutual funds do not need to be disclosed): Aviceda, Recens Medical, Retrotope, Polyphotonix</p>
Jorge Rocha	Nothing to disclose

The **planners and managers** have the following relevant financial relationships with ineligible companies:

Name of Planner or Manager	Reported Financial Relationship
Andrea Funk	Nothing to disclose
Yaremi Koopot	Nothing to disclose
Alana Ochoa	Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Clinical and Patient Educators Association (CPEA) and iVista do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Evaluation and Application for Credit Form

<https://ivista.digitellinc.com/ivista/live/160/page/1038>